Announcements Trials
Browse Landscape

Phase

Phase 2 50Phase 1 38Phase 1/2 31Phase NA 8Phase 3 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

pembrolizumab 1cemiplimab 1avelumab 1Nivolumab 1Ipilimumab 1Immune Checkpoint Inhibitors 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Merkel Cell × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡